Europa Biosite Secures New Growth Phase with EQT Acquisition
Deal News | Jul 03, 2025 | EQT
EQT Healthcare Growth has announced its acquisition of a majority stake in Europa Biosite, a distributor of high-quality research-use-only life science reagents and chemicals from Adelis Equity. The acquisition aims to support Europa Biosite's next phase of growth through a combination of commercial excellence initiatives, digital innovations, expanded product access, and a continued mergers and acquisitions strategy. With the support of EQT, which has a strong track record in specialised distribution with companies such as Azelis, Beijer Ref, and OEM International, Europa Biosite plans to enhance its own-brand offerings, expand geographically, and strengthen its local market presence through further acquisitions. The move is timely as the demand for research tools and scientific reagents continues to grow across its markets in Europe and North America. Leading the Board will be senior EQT advisor Kate Swann, with EQT set to provide valuable expertise in scaling distributors. The acquisition marks another step in EQT's continued growth and contribution to healthcare and life sciences sectors.
Sectors
- Life Sciences
- Investment and Private Equity
- Specialized Distribution
Geography
- Europe – Europa Biosite is headquartered in Stockholm and operates in 17 countries across Europe, making Europe a significant geographical area for this acquisition.
- North America – The company has a presence in North America, which indicates a target market for geographical expansion.
- Sweden – EQT and Europa Biosite are both headquartered in Sweden, marking it as the central location for corporate operations.
Industry
- Life Sciences – Europa Biosite operates within the life sciences sector by distributing high-quality research reagents, which are essential for scientific research and healthcare R&D.
- Investment and Private Equity – EQT, a private equity firm, is leading the acquisition and investment efforts to grow its portfolio, showcasing its activities and investments in the life sciences sector.
- Specialized Distribution – The acquisition involves Europa Biosite, a distributor of specialized life science products, which aligns with EQT's focus on scaling distribution operations.
Financials
- EUR 273 billion – Total assets under management by EQT as of March 31, 2025.
- EUR 142 billion – Fee-generating assets under management by EQT as of March 31, 2025.
- Over 10 million SKUs – The number of individual scientific products offered by Europa Biosite.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| EQT Healthcare Growth | Bidding Company, PE Firm | Company | A global private equity firm with a focus on healthcare growth, leading the acquisition of Europa Biosite. |
| Europa Biosite | Target Company | Company | A distributor of research-use-only life science reagents and chemicals, based in Sweden with operations in 17 countries. |
| Adelis Equity | Selling Company | Company | Private equity firm and the former majority owner of Europa Biosite, selling its stake to EQT. |
| Kate Swann | Chairperson of Europa Biosite | Person | Senior Industrial Advisor to EQT, appointed as Chairperson of Europa Biosite's Board. |
| Rikke Kjr Nielsen | Partner, EQT Healthcare Growth | Person | Partner in the EQT Healthcare Growth advisory team, involved in the acquisition strategy. |
| Sune Schmlker | CEO of Europa Biosite | Person | Chief Executive Officer of Europa Biosite, overseeing company operations and growth. |